ESTREL-Fatigue-association of levodopa with post-stroke fatigue.
Options
Publisher DOI
PubMed ID
41947565
Description
Introduction
Post-stroke fatigue (PSF) is common and impacts stroke rehabilitation. Dopaminergic treatment may have beneficial effects on PSF. This study investigated whether levodopa, compared with placebo, was associated with a lower frequency or severity of PSF during in-hospital rehabilitation.Patients And Methods
Enhancement of Stroke Rehabilitation with Levodopa (ESTREL)-Fatigue was an exploratory analysis of secondary outcome data obtained in the multicentre, randomised, placebo-controlled ESTREL trial. Participants with acute stroke received levodopa 100 mg/carbidopa 25 mg or placebo 3 times daily for 39 days to enhance motor recovery. Participants who (i) reported fatigue at 5 weeks and who (ii) took at least 80% of the study medication were included in ESTREL-Fatigue. No adjustments for confounding were made. The primary endpoint was the presence of PSF at 5 weeks, defined as a T-score of ≥ 55 on the Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue-Short-form-4a. As secondary endpoints, T-score cutoffs of ≥ 60 (moderate fatigue) and ≥ 70 (severe fatigue) were used. Binary logistic regression was used to compare PSF at 5 weeks between treatment groups. Results are presented as odds ratios (ORs) with 95% CI.Results
A total of 456 of 505 (90.3%) participants were included (levodopa/placebo 235/221, median age 73 years, 41% female). Post-stroke fatigue at 5 weeks was present in 63/235 (26.8%) levodopa-treated participants and in 65/221 (29.4%) placebo-treated participants (OR: 0.88; 95% CI, 0.58-1.32; risk ratio 0.91; risk difference - 2.6%). For cutoffs of ≥ 60 and ≥ 70, ORs were 0.78 (95% CI, 0.43-1.41) and 0.8 (95% CI, 0.25-2.44), respectively. A sensitivity analysis as per intention-to-treat with all 610 randomised ESTREL participants also showed no significant difference in fatigue presence between levodopa and placebo groups (OR: 0.95; 95% CI, 0.65-1.39) and a sensitivity analysis using a mixed-effects logistic regression showed no evidence of centre-related clustering.Conclusion
In ESTREL-Fatigue, levodopa, compared to placebo, was not associated with less PSF during in-hospital rehabilitation.
Post-stroke fatigue (PSF) is common and impacts stroke rehabilitation. Dopaminergic treatment may have beneficial effects on PSF. This study investigated whether levodopa, compared with placebo, was associated with a lower frequency or severity of PSF during in-hospital rehabilitation.Patients And Methods
Enhancement of Stroke Rehabilitation with Levodopa (ESTREL)-Fatigue was an exploratory analysis of secondary outcome data obtained in the multicentre, randomised, placebo-controlled ESTREL trial. Participants with acute stroke received levodopa 100 mg/carbidopa 25 mg or placebo 3 times daily for 39 days to enhance motor recovery. Participants who (i) reported fatigue at 5 weeks and who (ii) took at least 80% of the study medication were included in ESTREL-Fatigue. No adjustments for confounding were made. The primary endpoint was the presence of PSF at 5 weeks, defined as a T-score of ≥ 55 on the Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue-Short-form-4a. As secondary endpoints, T-score cutoffs of ≥ 60 (moderate fatigue) and ≥ 70 (severe fatigue) were used. Binary logistic regression was used to compare PSF at 5 weeks between treatment groups. Results are presented as odds ratios (ORs) with 95% CI.Results
A total of 456 of 505 (90.3%) participants were included (levodopa/placebo 235/221, median age 73 years, 41% female). Post-stroke fatigue at 5 weeks was present in 63/235 (26.8%) levodopa-treated participants and in 65/221 (29.4%) placebo-treated participants (OR: 0.88; 95% CI, 0.58-1.32; risk ratio 0.91; risk difference - 2.6%). For cutoffs of ≥ 60 and ≥ 70, ORs were 0.78 (95% CI, 0.43-1.41) and 0.8 (95% CI, 0.25-2.44), respectively. A sensitivity analysis as per intention-to-treat with all 610 randomised ESTREL participants also showed no significant difference in fatigue presence between levodopa and placebo groups (OR: 0.95; 95% CI, 0.65-1.39) and a sensitivity analysis using a mixed-effects logistic regression showed no evidence of centre-related clustering.Conclusion
In ESTREL-Fatigue, levodopa, compared to placebo, was not associated with less PSF during in-hospital rehabilitation.
Date of Publication
2026-03-01
Publication Type
Article
Keyword(s)
fatigue
•
levodopa
•
post-stroke fatigue
•
rehabilitation
•
stroke
Language(s)
en
Contributor(s)
Boos, Lukas | |
Kaufmann, Josefin E | |
Sauter, Mirjam I | |
Zietz, Annaelle | |
Trüssel, Simon | |
Engelter, Sophia V | |
Polymeris, Alexandros | |
Altersberger, Valerian L | |
Wiesner, Karin | |
Held, Jeremia P O | |
Rottenberger, Yannik | |
Schwarz, Anne | |
Foucras, Sandrine | |
Politz, Svetlana | |
Greulich, Matthias | |
Tarnutzer, Alexander A | |
Sturzenegger, Rolf | |
Katan, Mira | |
Schär, Janine | |
Deglon, Katrien Van Den Keybus | |
Rapin, Pierre-André | |
Salerno, Alexander | |
Schuster-Amft, Corina | |
Gäumann, Szabina | |
Möller, Jens Carsten | |
Schweinfurther, Raoul | |
Bujan, Bartosz | |
Jedrysiak, Piotr | |
Sandor, Peter S | |
Gonzenbach, Roman | |
Veit, Mylius | |
Lutz, Dietmar | |
Peters, Nils | |
Strambo, Davide | |
Schädelin, Sabine | |
Ford, Gary A | |
Kuppuswamy, Anna | |
Lerdal, Anners | |
Simpson, Dawn B | |
English, Coralie | |
Blackwell, Stewart | |
Gensicke, Henrik | |
Traenka, Christopher | |
Engelter, Stefan T |
Additional Credits
Series
European stroke journal
ISSN
2396-9881
Access(Rights)
metadata.only